English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial

Bulubas, L., Goerigk, S., Gomes, J. S., Brem, A.-K., Carvalho, J. B., Pinto, B. S., et al. (2021). Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial. SCHIZOPHRENIA RESEARCH, 235, 44-51. doi:10.1016/j.schres.2021.07.008.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Bulubas, Lucia1, Author           
Goerigk, Stephan, Author
Gomes, July S., Author
Brem, Anna-Katharine, Author
Carvalho, Juliana B., Author
Pinto, Bianca S., Author
Elkis, Helio, Author
Gattaz, Wagner F., Author
Padberg, Frank, Author
Brunoni, Andre R., Author
Valiengo, Leandro, Author
Affiliations:
1IMPRS Translational Psychiatry, Max Planck Institute of Psychiatry, Max Planck Society, ou_3318616              

Content

show
hide
Free keywords: -
 Abstract: Cognitive deficits and negative symptoms in schizophrenia are associated with poor functional outcomes and limited in terms of treatment. The Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) trial has shown efficacy of transcranial direct current stimulation (tDCS) for improving negative symptoms. In this secondary analysis, we investigate its effects on cognitive performance. In STARTS, a double-blinded, sham controlled, randomized clinical trial, patients were treated with twice-daily, 20-min, 2-mA fronto-temporal tDCS over 5 days or sham-tDCS. In 90 patients, we evaluated the cognitive performance up to 12 weeks post-treatment. We found that active-tDCS showed no beneficial effects over sham-tDCS in any of the tests. Based on a 5-factor cognitive model, improvements of executive functions and delayed memory were observed in favor of shamtDCS. Overall, the applied active-tDCS protocol, primarily designed to improve negative symptoms, did not promote cognitive improvement. We discuss possible protocol modification potentially required to increase tDCS effects on cognition. ClinicalTrials.gov identifier: NCT02535676

Details

show
hide
Language(s):
 Dates: 2021
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: SCHIZOPHRENIA RESEARCH
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 235 Sequence Number: - Start / End Page: 44 - 51 Identifier: ISSN: 0920-9964